Univariable analyses | Multivariable analyses | |||
---|---|---|---|---|
OR (95%CI) | OR (95% CI) | P value | ||
Outcome: LRTI N = 215 (152 adults, 63 children)a | ||||
Increasing age (by 10Y range) | All | 1.2 (1.0;1.3) | 1.1 (1.0;1.3) | 0.048 |
Adults | 1.3 (1.1;1.7) | 1.2 (1.0;1.5) | 0.128 | |
Children | 0.9 (0.3;2.8) | – | – | |
Bacterial co-infection | All | 3.3 (1.5;7.5) | 3.4 (1.5;8.2) | 0.005 |
Adults | 3.2 (1.3;8.6) | 3.4 (1.3;9.8) | 0.018 | |
Children | 3.4 (0.8;17.5) | 4.1 (0.9;24.6) | 0.084 | |
ALC | All | 1.0 (1.0;1.2) | 1.0 (1.0;1.2) | 0.501 |
Adults | 1.1 (1.0;1.3) | 1.0 (1.0;1.3) | 0.580 | |
Children | 1.0 (0.6;1.4) | 0.9 (0.6;1.3) | 0.457 | |
Type immunosuppression (compared to HSCT) | ||||
SOT | All | 0.9 (0.4;1.9) | 0.7 (0.3;1.4) | 0.294 |
Adults | 1.0 (0.4;2.1) | 0.7 (0.3;1.5) | 0.344 | |
Children | 0.7 (0.1;6.4) | – | – | |
Leukemia/lymphoma | All | 1.0 (0.5;2.0) | 1.0 (0.5;2.3) | 0.935 |
Adults | 2.0 (0.7;6.0) | 1.2 (0.4;3.9) | 0.791 | |
Children | 0.5 (0.1;2.7) | – | – | |
Solid tumor | All | 1.0 (0.4;2.5) | 1.0 (0.4;2.6) | 0.985 |
Adults | 1.2 (0.4;3.8) | 0.8 (0.2;2.8) | 0.718 | |
Children | 0.7 (0.1;4.4) | – | – | |
Chronic immunosuppressive medication | All | 3.4 (1.2;10.4) | 2.6 (0.9;8.3) | 0.077 |
Adults | 4.0 (1.3;15.6) | 2.4 (0.7;10.2) | 0.204 | |
Children | 2.0 (0.2;21.4) | – | – | |
PID | All | 0.6 (0.1;3.1) | 0.7 (0.1;4.3) | 0.724 |
Children | 0.7 (0.1;6.4) | – | – | |
Outcome: LRTI N = 215 (152 adults, 63 children)a | ||||
Increasing age (by 10Y range) | All | 1.2 (1.1;1.4) | 1.2 (1.1;1.4) | 0.003 |
Bacterial co-infection | All | 3.1 (1.5;6.6) | 3.6 (1.6;8.4) | 0.002 |
ALC | All | 1.0 (1.0;1.1) | 1.0 (1.0;1.1) | 0.439 |
Type immunosuppression (compared to HSCT) | ||||
SOT | All | 0.7 (0.3;1.7) | 0.5 (0.2;1.1) | 0.094 |
Leukemia/lymphoma | All | 0.9 (0.4;2.1) | 1.0 (0.4;2.5) | 0.956 |
Solid tumor | All | 1.2 (0.5;3.2) | 1.3 (0.4;3.6) | 0.639 |
Chronic immunosuppressive medication | All | 2.0 (0.8;5.4) | 1.4 (0.5;3.8) | 0.540 |
PID | All | 0.4 (0.0;2.8) | 0.7 (0.0;5.0) | 0.721 |